Parameswaran Venugopal to Female
This is a "connection" page, showing publications Parameswaran Venugopal has written about Female.
Connection Strength
0.355
-
Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma. Br J Haematol. 2017 Apr; 177(1):72-79.
Score: 0.044
-
Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia. Leuk Lymphoma. 2015; 56(11):3135-42.
Score: 0.039
-
Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients. Cancer. 2011 Apr 01; 117(7):1490-7.
Score: 0.028
-
Idiopathic hemophagocytic syndrome with a fulminant clinical course. Clin Adv Hematol Oncol. 2008 Aug; 6(8):587-90.
Score: 0.024
-
Recurrent thrombotic thrombocytopenic purpura treated repeatedly and successfully with the monoclonal antibody rituximab. Clin Adv Hematol Oncol. 2006 Mar; 4(3):215-7; discussion 217-8.
Score: 0.020
-
Relapsed non-Hodgkin lymphoma in fraternal twins managed successfully with rituximab maintenance therapy. Clin Adv Hematol Oncol. 2005 Feb; 3(2):136-9; discussion 139-40.
Score: 0.019
-
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood. 2021 01 21; 137(3):374-386.
Score: 0.014
-
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma. Invest New Drugs. 2020 10; 38(5):1448-1453.
Score: 0.013
-
Olaparib-Induced Severe Folate Deficiency in a Patient With Advanced Ovarian Cancer. J Oncol Pract. 2019 07; 15(7):405-407.
Score: 0.013
-
Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma. Br J Haematol. 2019 07; 186(1):45-53.
Score: 0.013
-
When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):e251-e258.
Score: 0.013
-
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
Score: 0.012
-
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2017 Nov 01; 35(31):3538-3546.
Score: 0.011
-
Impact of cachexia on outcomes in aggressive lymphomas. Ann Hematol. 2017 Jun; 96(6):951-956.
Score: 0.011
-
Bendamustine and Rituximab: Complete Response in a 62-Year-Old Female with an Aggressive Lymphoma and an Ejection Fraction of 20. Chemotherapy. 2017; 62(2):140-146.
Score: 0.011
-
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. J Clin Oncol. 2015 Apr 10; 33(11):1252-7.
Score: 0.010
-
Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients. J Leukoc Biol. 2013 Jan; 93(1):161-70.
Score: 0.008
-
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012 Nov; 13(11):1096-104.
Score: 0.008
-
Long-term remission of paroxysmal nocturnal hemoglobinuria following chemoimmunotherapy for non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2012 Feb; 10(2):134-6.
Score: 0.008
-
Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. Clin Lymphoma Myeloma Leuk. 2011 Dec; 11(6):467-74.
Score: 0.007
-
Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma. 2007 May; 7(6):406-12.
Score: 0.006
-
Posttransplant lymphoproliferative disorder: extranodal marginal zone lymphoma occurring after renal transplantation. Clin Adv Hematol Oncol. 2006 Aug; 4(8):600-4; discussion 604-6.
Score: 0.005
-
Durable remission of intravascular lymphoma with central nervous system involvement following chemotherapy and rituximab. Clin Adv Hematol Oncol. 2006 Jun; 4(6):439-41.
Score: 0.005
-
Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res. 2004 Aug; 28(8):791-803.
Score: 0.005
-
Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma. Clin Adv Hematol Oncol. 2004 Apr; 2(4):229-33.
Score: 0.004
-
Involvement of cyclin D1 and E2F1 in intramedullary apoptosis in myelodysplastic syndromes. J Hematother Stem Cell Res. 2003 Aug; 12(4):443-50.
Score: 0.004